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To the Editor,
Cushing’s disease (CD), a rare disorder of chronic hyper-
cortisolism caused by an adrenocorticotropic (ACTH)-
secreting pituitary adenoma, is associated with increased
mortality and complications including central obesity,
diabetes mellitus, osteoporosis, and cardiovascular disease
[1]. Transsphenoidal adenomectomy is generally first-line
treatment for CD but confirmation of surgical success and
diagnosis of recurrence can prove challenging [1]. We
endeavor to raise awareness of the complex, insidious
nature of CD recurrence through this illustrative case
report.
A 17-year-old female presented in 2006 with signs and
symptoms of CD including facial rounding and rubor,
hirsutism, alopecia, proximal muscle weakness, acne,
stretch marks, weight gain, fatigue, insomnia, emotional
fluctuations, headaches, and heartburn. She had elevated
24-hour urinary free cortisol [UFC; 126.5 lg/24 h (normal,
\80)], and plasma ACTH [61 pg/mL (normal \48)]. Her
dexamethasone suppression/corticotropin-releasing hor-
mone stimulation test (Dex/CRH) was positive (serum
cortisol 6.0 lg/dL 15 min after CRH) and magnetic reso-
nance imaging (MRI) showed a 1.1-cm hypoenhancing
pituitary lesion, confirming CD diagnosis (Fig. 1a).
After transsphenoidal surgery in December 2006, cor-
ticotroph adenoma was histologically confirmed. Consis-
tent with CD remission, nadir serum cortisol measurement
of 1.1 lg/dL (normal range 7.0–23.0) was recorded at
8 a.m. within 72 h post-surgery. Over the ensuing months,
the patient reported decreased acne, heartburn, and proxi-
mal muscle weakness. Her face thinned and she lost 55
pounds.
Beginning 6 months after surgery, she reported that her
previous symptoms began to return episodically several
times per year. In February 2011, her symptoms (weight
gain, acne, fatigue, and proximal muscle weakness)
became unremitting. At this time, however, 24-h UFC and
Dex/CRH tests were normal. She was noted to have ele-
vated morning serum cortisol (peak, 31.5 lg/dL), but lev-
els normalized after oral estrogen was discontinued. A
follow-up MRI showed no pituitary lesion (Fig. 1b).
Despite consistently normal biochemical assessments
(13 salivary cortisol tests, seven 24-h UFCs, three Dex/
CRH tests, and one overnight Dex suppression test) over
the 5-year period since pituitary surgery, the patient’s Dex/
CRH levels ultimately became strongly positive (7.9 lg/dL
15 min after CRH; Dex level: 571 ng/dL) in late 2011.
Based on the positive Dex/CRH result plus strong symp-
tomatic and physical features of recurrent CD, the patient
underwent repeat pituitary surgery. Corticotroph adenoma
was again identified, removed, and confirmed by positive
immunohistochemical staining for ACTH (Fig. 1c). Post-
surgery, serum cortisol was measured every 6 h and, con-
sistent with remission and possible complete removal of
the adenoma, levels decreased to 0.9 lg/dL (normal
6.2–19.0) within 72 h. Her CD symptoms resolved and
follow-up biochemistry was negative.
This case study illustrates the complexities of identify-
ing patients with post-surgical recurrent CD. Within
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4 years of apparent surgical remission, the patient experi-
enced returning symptoms despite normal UFC and Dex/
CRH tests. Ultimately, however, once she had biochemical
evidence of CD recurrence (i.e., positive Dex/CRH despite
continued normal UFC), she underwent repeat pituitary
surgery and corticotroph adenoma was histologically con-
firmed. While subnormal immediate post-operative serum
cortisol (as detected in this patient after her initial surgery)
generally portends lasting remission, recurrence is still a
possibility and occurs in approximately 6–12 % of such
cases [2]. Similarly, normal UFC and/or midnight salivary
cortisol levels are not reliable predictors of sustained
remission per se. Careful follow up is required for all post-
surgical CD patients and, if recurrence is suspected, bio-
chemical test results should be interpreted in the context of
clinical signs and symptoms.
CD has been associated with a 1.84- to 4.8-fold increase
in mortality compared with the general population [3, 4].
However, many features of cortisol excess (e.g., obesity,
depression, diabetes, hypertension, dyslipidemia) are
common in the general population [1]. Given that 10-year
post-surgical recurrence rates for CD may be as high as
56 % [5], postoperative CD patients should be meticu-
lously monitored for persistence and recurrence of disease.
When this patient presented, no medical therapies were
yet indicated for treatment of recurrent CD. Since that time,
however, treatment options have expanded and clinicians
have more choices for treating refractory cases. The US FDA
has approved mifepristone (a glucocorticoid receptor
antagonist) for treatment of hyperglycemia associated with
Cushing’s syndrome [6], and pasireotide (a multireceptor-
targeted somatostatin analog) for treatment of adults with
CD who are not surgical candidates [7]. Choice of therapy
depends on several factors including the patient’s overall
surgical risk, severity of hypercortisolism, and patient pref-
erences—particularly with respect to fertility. Regardless of
treatment choice, special attention should be given to
recurring symptoms as these may indicate early signs of
disease even before biochemical evidence is present.
Appropriate management is crucial, even when conflicting
results make clinical decisions challenging.
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bFig. 1 a Initial (2006) pre-operative T1 dynamic contrast-enhanced
MRI (field strength 1.5 T) showing a 1.1-cm pituitary lesion.
b Follow-up (2011) MRI with no lesion noted. c ACTH immunostain
confirming recurrent CD
192 J Neurooncol (2014) 117:191–193
123
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden
of Cushing’s disease: clinical and health-related quality of life
aspects. Eur J Endocrinol 167:311–326
2. Sughrue ME, Shah JK, Devin JK, Kunwar S, Blevins LS (2010)
Utility of the immediate postoperative cortisol concentrations in
patients with Cushing’s disease. Neurosurgery 67:688–695
3. Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011)
Mortality and morbidity in Cushing’s disease over 50 years in
stoke-on-trent, UK: audit and meta-analysis of literature. J Clin
Endocrinol Metab 96:632–642
4. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jorgen-
sen JO (2012) Mortality in Cushing’s syndrome: a systematic
review and meta-analysis. Eur J Intern Med 23:278–282
5. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B
(2005) Long-term remission rates after pituitary surgery for
Cushing’s disease: the need for long-term surveillance. Clin
Endocrinol (Oxf) 63:549–559
6. KorlymTM (mifepristone) full prescribing information. Corcept
Therapeutics Incorporated. Menlo Park, CA. Feb 2012. http://www.
korlym.com/docs/KorlymPrescribingInformation.pdf. Accessed 27
June 2013
7. Signifor (pasireotide) full prescribing information. Novartis
Pharma Stein AG. Stein, Switzerland. December 2012. http://
www.pharma.us.novartis.com/product/pi/pdf/signifor.pdf?site=PC
009650&source=01030. Accessed 27 June 2013
J Neurooncol (2014) 117:191–193 193
123
